Literature DB >> 18172656

Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas.

Ulrich Schüller, Michael Ruiter, Jochen Herms, Hans A Kretzschmar, Eva Grasbon-Frodl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18172656     DOI： 10.1007/s00401-007-0334-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  6 in total

Review 1.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

2.  Targeted therapy in the treatment of malignant gliomas.

Authors:  Rimas V Lukas; Adrienne Boire; M Kelly Nicholas
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

3.  The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.

Authors:  I S Mahmoud; M A Sughayer; H A Mohammad; A S Awidi; M S EL-Khateeb; S I Ismail
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

4.  Absence of AKT1 mutations in glioblastoma.

Authors:  Fonnet E Bleeker; Simona Lamba; Carlo Zanon; Angela A van Tilborg; Sieger Leenstra; Dirk Troost; Theo Hulsebos; W Peter Vandertop; Alberto Bardelli
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

5.  Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting.

Authors:  Hongdo Do; Benjamin Solomon; Paul L Mitchell; Stephen B Fox; Alexander Dobrovic
Journal:  BMC Res Notes       Date:  2008-05-16

6.  Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand.

Authors:  Anna J Khalaj; Jaehee Yoon; Jaspreet Nakai; Zachary Winchester; Spencer M Moore; Timothy Yoo; Leonardo Martinez-Torres; Shalini Kumar; Noriko Itoh; Seema Kaushalya Tiwari-Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.